4 research outputs found
Effects of Vitamin D treatment on thyroid autoimmunity
No full textBackground: Vitamin D was shown to be related to autoimmune thyroid diseases (AITDs) in the previous studies. We aimed to investigate the relationship between Vitamin D and thyroid autoimmunity. Materials and Methods: Eighty-two patients, diagnosed with AITD by the endocrinology outpatient clinic, were included in this prospective study. All of the patients had both AITD and Vitamin D deficiency, defined as serum values <20 ng/mL. They were randomly assigned into two groups. The first group included 46 patients and the second one included 36 patients. The first group was treated with Vitamin D for 1 month at 1000 IU/day. The second group served as the control group and was not treated with Vitamin D replacement. Serum thyroid-stimulating hormone, free T4 (fT4), thyroid peroxidase antibody (TPO-Ab), thyroglobulin antibody (TgAb), and Vitamin D levels were measured at the initiation of the study and again at 1 month in all patients. Results: Two groups were similar with regard to age, sex, and type of thyroid disease. Whereas TPO-Ab (before; 278.3 ± 218.4 IU/ml and after; 267.9 ± 200.7 IU/ml) and TgAb (before; 331.9 ± 268.1 IU/ml and after; 275.4 ± 187.3 IU/ml) levels were significantly decreased by the Vitamin D replacement therapy in group 1 (P = 0.02, P = 0.03, respectively), the evaluated parameters in the control group did not significantly change (P = 0.869, P = 0.530, respectively). In addition, thyroid function tests did not significantly change with Vitamin D replacement in two groups. Conclusion: Vitamin D deficiency may contribute to the pathogenesis of AITDs. Since supplementation of the Vitamin D decreased thyroid antibody titers in this study in Vitamin D deficient subjects, in the future Vitamin D may become a part of AITDs' treatment, especially in those with Vitamin D insufficiency. Further clinical and experimental studies are required to understand the effect of Vitamin D on AITD
Changes in Lipid Profile and Body Mass Index in Patients with Subclinical Hypothyroidism: Evaluation of L-Thyroxine Treatment
No full textIntroduction: Subclinical hypothyroidism is defined as a mild elevation
in serum thyroid stimulating hormone (TSH) level, while serum free T4
(FT4) and free T3 (FT3) levels are within the reference range. The main
problem with these patients is whether they should receive therapy or
not. In many studies, positive effects of levothyroxine treatment on
hypothyroidism symptoms, serum lipid levels and cardiac functions are
shown. In this prospective clinical study, we aimed to evaluate the
metabolic changes in newly diagnosed subclinical hypothyroidism
patients who were administered thyroxine.
Methods: Sixty-three newly diagnosed patients with subclinical
hypothyroidism were included in the study. Randomly chosen 36
patients receiving therapy constituted the study group, while the
remaining 27 patients formed the control group and were followed
without any treatment. The patients were questioned for symptoms
and examined thoroughly at the beginning of the study and at the end
of the third month. Thyroid function tests, lipid parameters and body
mass index (BMI) were determined at both the beginning and the end
of the study.
Results: There were 32 (88.8%) female and 4 (11.2%) male
patients in the study group; mean values of age and BMI were
44.66±13.34 years and 29.96±5.99 kg/m², respectively. The control
group consisted of 23 (85.2%) female and 4 (14.8%) male patients;
their mean values of age and BMI were 42.51±11.66 years and
30.68±5.61 kg/m², respectively. Mean TSH levels and mean fT3 levels
were significantly decreased in the third month with respect to the
beginning in patients receiving treatment when compared to the
control group. In the beginning, the mean levels of serum LDL
cholesterol were 127.55±44.69 mg/dl and 112.37±30.43 mg/dl in the
study and control groups, respectively. Mean LDL cholesterol level
showed a significant increase in the control group at three-month
follow-up visit (p=0.041).
Discussion: In this study, we found that the symptoms of clinical
hypothyroidism mostly existed in patients with subclinical
hypothyroidism, and clinical and metabolic parameters improved with
levothyroxine therapy. (The Me di cal Bul le tin of Ha se ki 2011; 49: 131-6
